secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autonomix Medical, Inc. (AMIX)
CIK:        0001617867
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001437749-25-013631
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autonomix PoC1 trial meets objectives; initiates PoC2 expansion study for visceral cancer pain
--------------------------------------------------------------------------------

- All 20 patients enrolled; 19 treated via transvascular RF ablation; 84% femoral-access responders achieved 53.3% mean VAS pain reduction at 7 days.
- 100% of responding patients zero opioid use at 7 days post-procedure; 73% remained opioid-free at 4-6 weeks follow-up.
- No device- or procedure-related serious adverse events; 6 subjects died from disease progression unrelated to the procedure.
- PoC2 phase begins Q2 2025, targeting additional visceral cancers (liver, gall bladder, bile duct) and earlier-stage pancreatic cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617867/000143774925013631/0001437749-25-013631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617867/000143774925013631/amix20250429_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-013631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer